| Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program. | |
| | |
MedLine Citation:
|
PMID: 21666152 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Background. Measles control has succeeded worldwide, and many countries have substantially reduced incidence and mortality. This has led to consideration of the feasibility of measles elimination in Uganda within the context of global eradication. Before an elimination program is initiated, it is important to consider its potential economic impact, including its cost-effectiveness. Methods. Incremental cost-effectiveness ratios (ICERs) were estimated for measles mortality reduction and measles elimination in Uganda. A dynamic age-structured compartmental model of measles transmission was used to simulate scenarios and estimate health outcomes and costs. The main outcome measures were costs, measles cases, measles deaths, disability-adjusted life-years (DALYs), and ICERs measured as cost per DALY averted through either the year 2030 or 2050. Results. Measles elimination by 2020 averted 130,232 measles cases, 3520 measles deaths, and 106,330 DALYs through the year 2030, compared with the next best scenario (95% mortality reduction by 2015), and it was the most cost-effective strategy, with ICERs of $556 per DALY averted (2030 time horizon) and $284 per DALY averted (2050 time horizon). Conclusions. Measles elimination in Uganda, as part of a global eradication program, is projected to be highly cost-effective and should be considered among the available policy options for dealing with the disease. |
| | |
Authors:
|
Joseph B Babigumira; Ann Levin; Colleen Burgess; Louis P Garrison; Chris T Bauch; Fiona Braka; William B Mbabazi; Juliet O Nabyonga; Emily Simons; Alya Dabbagh |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of infectious diseases Volume: 204 Suppl 1 ISSN: 1537-6613 ISO Abbreviation: J. Infect. Dis. Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-06-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0413675 Medline TA: J Infect Dis Country: United States |
Other Details:
|
Languages: eng Pagination: S116-23 Citation Subset: AIM; IM |
Affiliation:
|
Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for ...
Next Document: Using cost-effectiveness analysis to support research and development portfolio prioritization for p...